Clinical Trial

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 24, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-06; most recent amendment 2025-11-19.
Trial Details
NCT Number NCT06126731
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Prostate Cancer Foundation
Conditions Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enrollment 39 participants
Start Date 2023-11-02
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-24